KLK3 and prostate cancer: With baseline adjustment for age, race, care site, BMI, and recent hospitalization, and time-varying adjustment for medical comorbidities, repeated testosterone testing and PSA screening intensity, there was no difference in risk of aggressive prostate cancer in testosterone-treated versus untreated men: hazard ratio (HR) 0.89; 95% CI 0.70–1.13 (Table 4).